![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Bangladesh Court Upholds Ruling Barring 34 Drugmakers from Manufacturing Therapies
Bangladesh Court Upholds Ruling Barring 34 Drugmakers from Manufacturing Therapies
February 21, 2017
A Bangladesh high court sustained a ruling from last year that barred 20 drugmakers from manufacturing therapies because of substandard production.
The court upheld the order, which barred drugmakers — including Bikalpa Pharmaceutical, Dolphin Pharmaceuticals, Drugland, Exim Pharmaceutical, Globe Laboratories, Jalpa Laboratories and Kafina Pharmaceuticals — from manufacturing products after holding a hearing on the injunction.
The order also requires that 14 other drugmakers no longer manufacturer antibiotics. The companies include Belsen Pharmaceuticals, Bengal Drugs and Chemicals, Bristol Pharma, Crystal Pharmaceuticals, Indo-Bangla Pharmaceuticals and Millat Pharmaceuticals.
Upcoming Events
-
21Oct